Eloxx Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing small-molecule drugs that coax the body's protein-building machinery to "read through" genetic errors called nonsense mutations, which cause rare diseases like Alport syndrome. Its lead investigational drug, exaluren, aims to restore full-length functional proteins in patients with these conditions. Founded in 2013 by two scientists, the company went public in 2017 through a reverse merger with Sevion Therapeutics, and its name echoes the "ELX" prefix of its drug compounds.
Granted 1.14M · Bought 1.97M
Granted 2.53M · Bought 2.47M
Bought 87.8K
Bought 300.0K
Granted 40.2K · Bought 1.14M
Bought 6.49M
Bought 6.49M
Granted 1.06M
Bought 6.49M
Granted 1.95M
Granted 896.5K · Bought 35.0K
Granted 133.7K · Bought 208.0K
Granted 495.1K
Granted 20.1K · Bought 180.6K
Granted 432.8K · Bought 15.0K
Granted 219.3K
Granted 117.2K
Granted 490.8K
Granted 137.7K
Granted 104.4K
Granted 307.5K · Bought 3.5K · Sold 74.5K
Granted 117.3K · Sold 17.0K
Granted 15.0K · Bought 41.2K
Bought 50.0K
Granted 65.0K
Granted 1.9K · Bought 9.7K
Granted 46.9K
Granted 15.8K
Granted 55.3K
Granted 17.6K
Granted 289.9K · Bought 89.6K
Granted 8.8K · Bought 4.5K
Granted 10.9K
Granted 10.0K · Bought 23.0K
Bought 2.3K
Bought 49.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Klaver Paul Edward10% owner · 4 transactions | — | 45.73Mas of Mar 2012 | — | — | — |
| Forbes ChristopherDirector, 10% owner · 74 transactions | — | 12.76Mas of Nov 2012 | 1.14M | 1.97M | — |
| Parekh Rajesh BDirector · 4 transactions | — | 7.44Mas of May 2021 | 2.53M | 2.47M | — |
| Shabtai Gilad10% owner · 4 transactions | — | 3.35Mas of Apr 2018 | — | 87.8K | — |
| Kleijwegt MartijnDirector · 1 transaction | — | 2.95Mas of Apr 2018 | — | 300.0K | — |
| Waksal HarlanDirector · 9 transactions | — | 2.81Mas of Aug 2012 | 40.2K | 1.14M | — |
| Kariv TomerDirector · 17 transactions | — | 2.29Mas of May 2021 | — | 6.49M | — |
| Nussbaum RanDirector · 17 transactions | — | 2.29Mas of May 2021 | — | 6.49M | — |
| Smider VaughnChief Scientific Officer, Director · 2 transactions | — | 2.12Mas of May 2014 | 1.06M | — | — |
| Pontifax (Cayman) IV L.P. +4 co-filers10% owner · 17 transactions | — | 1.79Mas of May 2021 | — | 6.49M | — |
| Aggarwal SumitPresident and CEO, Director, 10% owner · 8 transactions | — | 1.67M | 1.95M | — | — |
| Frost Phillip MD Et Al +1 co-filerDirector, 10% owner, 10% owner · 2 transactions | — | 1.60Mas of Sep 2015 | 896.5K | 35.0K | — |
| Stalder RuediDirector · 12 transactions | — | 1.32Mas of Sep 2011 | 133.7K | 208.0K | — |
| Opko Health, Inc.10% owner · 4 transactions | — | 1.29Mas of Dec 2017 | 495.1K | — | — |
| Domicilium Real Estate Fund III LP10% owner · 3 transactions | — | 642.9K | — | — | — |
| Rector DavidDirector · 15 transactions | — | 352.8Kas of Nov 2012 | 20.1K | 180.6K | — |
| Ward RobertFORMER CHAIRMAN AND CEO · 15 transactions | — | 267.6Kas of Feb 2020 | 432.8K | 15.0K | — |
| Modur VijayHEAD OF R&D · 2 transactions | — | 219.3Kas of Dec 2021 | 219.3K | — | — |
| Fedyszyn Sascha PVP - Corporate Dev. · 4 transactions | — | 153.5Kas of Nov 2009 | 117.2K | — | — |
| Noiman SilviaChief Executive Officer, Director · 2 transactions | — | 141.4Kas of Jun 2018 | 490.8K | — | — |
| Huertas PedroChief Medical Officer · 2 transactions | — | 137.7Kas of May 2018 | 137.7K | — | — |
| Graziano James JosephChief Technology Officer · 1 transaction | — | 104.4Kas of May 2014 | 104.4K | — | — |
| Galton Bruce CFormer President & CEO · 17 transactions | — | 98.5Kas of Dec 2009 | 307.5K | 3.5K | 74.5K |
| Brooks JoelCFO and Treasurer · 8 transactions | — | 90.9Kas of Nov 2009 | 117.3K | — | 17.0K |
| Braca John NDirector · 17 transactions | — | 58.6Kas of May 2010 | 15.0K | 41.2K | — |
| Geffken Daniel E.INTERIM CFO · 1 transaction | — | 50.0Kas of Nov 2021 | — | 50.0K | — |
| Williams Gregory C.CHIEF EXECUTIVE OFFICER, Director · 12 transactions | — | 44.6Kas of Feb 2021 | 65.0K | — | — |
| Van Hulst JackDirector · 7 transactions | — | 40.1Kas of May 2010 | 1.9K | 9.7K | — |
| Belloff Neil S.COO, GENERAL COUNSEL &CORP SEC · 18 transactions | — | 33.2Kas of Jul 2021 | 46.9K | — | — |
| Androski LindsayDirector · 2 transactions | — | 15.8Kas of Jan 2025 | 15.8K | — | — |
| Walts Alan EdmundDirector · 4 transactions | — | 15.6K | 55.3K | — | — |
| Rubin Steven DDirector · 3 transactions | — | 14.6K | 17.6K | — | — |
| Quick Thomas CDirector · 9 transactions | — | 13.1Kas of May 2014 | 289.9K | 89.6K | — |
| Weaver Gregory LFORMER CHIEF FINANCIAL OFFICER · 5 transactions | — | 11.5Kas of Mar 2020 | 8.8K | 4.5K | — |
| Snow David P.FORMER CHIEF BUSINESS OFFICER · 4 transactions | — | 7.4Kas of Feb 2020 | 10.9K | — | — |
| Isabelle Warren JohnDirector · 8 transactions | — | 6.0Kas of May 2014 | 10.0K | 23.0K | — |
| Avnur ZafriraDirector · 2 transactions | — | 2.3Kas of Mar 2018 | — | 2.3K | — |
| Browne Leslie JPresident and CEO, Director · 6 transactions | — | 1.3Kas of Dec 2013 | — | 49.8K | — |
| Coastlands Capital LP10% owner · 1 transaction | — | 0 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +26.05M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.